News | June 24, 2024
EMA approves Biocon Biologics’ new mAbs facility in India
Renews GMP certifications for India and Malaysia sites
Renews GMP certifications for India and Malaysia sites
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
